Related Experiment Videos
A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis
Melanie S Joy1, Susan L Hogan, J Charles Jennette
1Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Summary
Mycophenolate mofetil (MMF) offers a safe and effective treatment for ANCA vasculitis, reducing disease activity without immediate need for cytotoxic agents. This pilot study shows MMF is a viable option for managing this condition.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Antineutrophil cytoplasmic autoantibody (ANCA) vasculitis treatment carries risks from long-term corticosteroids and cytotoxic agents.
- Exploring safer alternatives is crucial to minimize patient risks.
- This study investigates mycophenolate mofetil (MMF) for non-life-threatening ANCA vasculitis.
Purpose of the Study:
- To evaluate the efficacy and safety of MMF in treating ANCA vasculitis.
- To assess MMF's potential to reduce reliance on traditional therapies.
- To explore MMF as an alternative for recurrent or cyclophosphamide-resistant cases.
Main Methods:
- Pilot study involving twelve subjects with ANCA vasculitis.
- MMF dosage: initiated at 500 mg twice daily, escalated to 1000 mg twice daily for 24 weeks.
- Disease activity assessed by Birmingham Vasculitis Activity Score (BVAS); ANCA titres, creatinine, and adverse events were secondary measures.
Main Results:
- MMF treatment significantly improved BVAS scores at 24 and 52 weeks compared to baseline (P = 0.0013 and P = 0.0044).
- Average BVAS decreased from 9.1 at baseline to 2.8 at 24 weeks and remained low at 52 weeks.
- Reductions in BVAS were observed in both relapsed and treatment-resistant cases; side effect profile was consistent with MMF.
Conclusions:
- MMF is a viable treatment option for non-life-threatening recurrent or resistant ANCA vasculitis.
- MMF may reduce the immediate need for repeated use of cytotoxic agents.
- Further research into MMF for ANCA vasculitis is warranted.